The findings can be used in patient counseling. Research confirms the clinical benefit of assessing bone biomarkers in hormone-sensitive prostate cancer.
Jonathan W. Riess, MD, MS, discusses how prior data led to the investigation of IO102-IO103 in combination with pembrolizumab in patients with PD-L1–high non–small cell lung cancer adenocarcinoma and details the initial efficacy and safety data reported in this population.
There may actually be a way to kill cancer cells with a “kill switch.” Researchers from the University of California Davis Comprehensive Cancer Center in Sacramento, California say they have discovered a crucial epitope (a protein section that can activate the larger protein) on the CD95 receptor that can simply make the cancer cells die. […]
For patients with clear cell renal cell carcinoma (RCC) at very high risk for recurrence, adjuvant everolimus is associated with significantly improved recurrence-free survival.